PLoS ONE · 2015 · 51 citations · 28 references
MedicineMolecular BiologyOncologyMolecular OncologyOncogenesTumor ProgressionCancer Molecular DiagnosticsCancer ProgressionCirculating Tumor CellsColorectal CancerMalignant NeoplasmsMolecular Tumor ProfilingCirculating Tumor Cell CharacterizationCirculating Tumor Cell Molecular ProfilingEnrichment Of Rare CellsMolecular Marker ProfilingMolecular Profiling From BiopsyPrimary Tumor CharacterizationTumor Mutation DetectionTumor Mutational Profiling
Circulating tumor cells (CTCs) provide a non-invasive accessible source of tumor material from patients with cancer. The cellular heterogeneity within CTC populations is of great clinical importance regarding the increasing number of adjuvant treatment options for patients with metastatic carcinomas, in order to eliminate residual disease. Moreover, the molecular profiling of these rare cells might lead to insight on disease progression and therapeutic strategies than simple CTCs counting. In the present study we investigated the feasibility to detect KRAS, BRAF, CD133 and Plastin3 (PLS3) mutations in an enriched CTCs cell suspension from patients with colorectal cancer, with the hypothesis that these genes` mutations are of great importance regarding the generation of CTCs subpopulations. Subsequently, we compared CTCs mutational status with that of the corresponding primary tumor, in order to access the possibility of tumor cells characterization without biopsy. CTCs were detected and isolated from blood drawn from 52 colorectal cancer (CRC) patients using a quantum-dot-labelled magnetic immunoassay method. Mutations were detected by PCR-RFLP or allele-specific PCR and confirmed by direct sequencing. In 52 patients, discordance between primary tumor and CTCs was 5.77% for KRAS, 3.85% for BRAF, 11.54% for CD133 rs3130, 7.69% for CD133 rs2286455 and 11.54% for PLS3 rs6643869 mutations. Our results support that DNA mutational analysis of CTCs may enable non-invasive, specific biomarker diagnostics and expand the scope of personalized medicine for cancer patients.
28
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al. · New England Journal of Medicine · 2009 · 3.9K citations · Full text
Medicine, Oncology, Pharmacology +17
Cetuximab for the Treatment of Colorectal Cancer
Derek J. Jonker, Chris J. O’Callaghan, Christos S. Karapetis et al. · New England Journal of Medicine · 2007 · 1.8K citations · Full text
Medicine, Oncology, Pharmacology +17
Cetuximab in the treatment of colorectal cancer.
Richard M. Goldberg, Alan P. Venook, Richard L. Schilsky · PubMed · 2004 · 1.5K citations
Medicine, Oncology, Pharmacology +10